Tumor biology, biomarkers, and liquid biopsy in pediatric renal tumors

Amy L. Walz; Mariana Maschietto; Brian Crompton; Nicholas Evageliou; David Dix; Godelieve Tytgat; Manfred Gessler; David Gisselsson; Najat C. Daw; Jenny Wegert

doi:10.1002/pbc.30130

Tumor biology, biomarkers, and liquid biopsy in pediatric renal tumors

Amy L. Walz, Mariana Maschietto, Brian Crompton, Nicholas Evageliou, David Dix, Godelieve Tytgat, Manfred Gessler, David Gisselsson, Najat C. Daw, Jenny Wegert^*

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Review article › peer-review

Abstract

The expansion of knowledge regarding driver mutations for Wilms tumor (WT) and malignant rhabdoid tumor of the kidney (MRT) and various translocations for other pediatric renal tumors opens up new possibilities for diagnosis and treatment. In addition, there are growing data surrounding prognostic factors that can be used to stratify WT treatment to improve outcomes. Here, we review the molecular landscape of WT and other pediatric renal tumors as well as WT prognostic factors. We also review incorporation of circulating tumor DNA/liquid biopsies to leverage this molecular landscape, with potential use in the future for distinguishing renal tumors at the time of diagnosis and elucidating intratumor heterogeneity, which is not well evaluated with standard biopsies. Incorporation of liquid biopsies will require longitudinal collection of multiple biospecimens. Further preclinical research, identification and validation of biomarkers, molecular studies, and data sharing among investigators are crucial to inform therapeutic strategies that improve patient outcomes.

Original language	English (US)
Journal	Pediatric Blood and Cancer
DOIs	https://doi.org/10.1002/pbc.30130
State	Accepted/In press - 2023

Keywords

Wilms tumor
biomarkers
liquid biopsy
pediatric renal tumors
tumor biology

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.30130

Cite this

@article{3c8e47d3f2cf42fdabafa89c5c3a0eb4,

title = "Tumor biology, biomarkers, and liquid biopsy in pediatric renal tumors",

abstract = "The expansion of knowledge regarding driver mutations for Wilms tumor (WT) and malignant rhabdoid tumor of the kidney (MRT) and various translocations for other pediatric renal tumors opens up new possibilities for diagnosis and treatment. In addition, there are growing data surrounding prognostic factors that can be used to stratify WT treatment to improve outcomes. Here, we review the molecular landscape of WT and other pediatric renal tumors as well as WT prognostic factors. We also review incorporation of circulating tumor DNA/liquid biopsies to leverage this molecular landscape, with potential use in the future for distinguishing renal tumors at the time of diagnosis and elucidating intratumor heterogeneity, which is not well evaluated with standard biopsies. Incorporation of liquid biopsies will require longitudinal collection of multiple biospecimens. Further preclinical research, identification and validation of biomarkers, molecular studies, and data sharing among investigators are crucial to inform therapeutic strategies that improve patient outcomes.",

keywords = "Wilms tumor, biomarkers, liquid biopsy, pediatric renal tumors, tumor biology",

author = "Walz, {Amy L.} and Mariana Maschietto and Brian Crompton and Nicholas Evageliou and David Dix and Godelieve Tytgat and Manfred Gessler and David Gisselsson and Daw, {Najat C.} and Jenny Wegert",

note = "Funding Information: This work was supported in part by the Norman Jaffe Professorship in Pediatrics Endowment Fund, the University of Texas MD Anderson Cancer Center, Houston, TX. The authors would like to acknowledge HARMONICA, the joint initiative between the COG Renal Tumor Committee and the SIOP Renal Tumor Study Group that enabled this international collaborative effort. Publisher Copyright: {\textcopyright} 2022 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.",

year = "2023",

doi = "10.1002/pbc.30130",

language = "English (US)",

journal = "Medical and Pediatric Oncology",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Tumor biology, biomarkers, and liquid biopsy in pediatric renal tumors

AU - Walz, Amy L.

AU - Maschietto, Mariana

AU - Crompton, Brian

AU - Evageliou, Nicholas

AU - Dix, David

AU - Tytgat, Godelieve

AU - Gessler, Manfred

AU - Gisselsson, David

AU - Daw, Najat C.

AU - Wegert, Jenny

N1 - Funding Information: This work was supported in part by the Norman Jaffe Professorship in Pediatrics Endowment Fund, the University of Texas MD Anderson Cancer Center, Houston, TX. The authors would like to acknowledge HARMONICA, the joint initiative between the COG Renal Tumor Committee and the SIOP Renal Tumor Study Group that enabled this international collaborative effort. Publisher Copyright: © 2022 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.

PY - 2023

Y1 - 2023

N2 - The expansion of knowledge regarding driver mutations for Wilms tumor (WT) and malignant rhabdoid tumor of the kidney (MRT) and various translocations for other pediatric renal tumors opens up new possibilities for diagnosis and treatment. In addition, there are growing data surrounding prognostic factors that can be used to stratify WT treatment to improve outcomes. Here, we review the molecular landscape of WT and other pediatric renal tumors as well as WT prognostic factors. We also review incorporation of circulating tumor DNA/liquid biopsies to leverage this molecular landscape, with potential use in the future for distinguishing renal tumors at the time of diagnosis and elucidating intratumor heterogeneity, which is not well evaluated with standard biopsies. Incorporation of liquid biopsies will require longitudinal collection of multiple biospecimens. Further preclinical research, identification and validation of biomarkers, molecular studies, and data sharing among investigators are crucial to inform therapeutic strategies that improve patient outcomes.

AB - The expansion of knowledge regarding driver mutations for Wilms tumor (WT) and malignant rhabdoid tumor of the kidney (MRT) and various translocations for other pediatric renal tumors opens up new possibilities for diagnosis and treatment. In addition, there are growing data surrounding prognostic factors that can be used to stratify WT treatment to improve outcomes. Here, we review the molecular landscape of WT and other pediatric renal tumors as well as WT prognostic factors. We also review incorporation of circulating tumor DNA/liquid biopsies to leverage this molecular landscape, with potential use in the future for distinguishing renal tumors at the time of diagnosis and elucidating intratumor heterogeneity, which is not well evaluated with standard biopsies. Incorporation of liquid biopsies will require longitudinal collection of multiple biospecimens. Further preclinical research, identification and validation of biomarkers, molecular studies, and data sharing among investigators are crucial to inform therapeutic strategies that improve patient outcomes.

KW - Wilms tumor

KW - biomarkers

KW - liquid biopsy

KW - pediatric renal tumors

KW - tumor biology

UR - http://www.scopus.com/inward/record.url?scp=85145404339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85145404339&partnerID=8YFLogxK

U2 - 10.1002/pbc.30130

DO - 10.1002/pbc.30130

M3 - Review article

C2 - 36592003

AN - SCOPUS:85145404339

SN - 1545-5009

JO - Medical and Pediatric Oncology

JF - Medical and Pediatric Oncology

ER -

Tumor biology, biomarkers, and liquid biopsy in pediatric renal tumors

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this